Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
Yuankai Shi, Jian Fang, Ligang Xing, Yu Yao, Jian Zhang, Lian Liu, Yongsheng Wang, Changlu Hu, Jianping Xiong, Zhihua Liu, Runxiang Yang, Zhen Wang, Enfeng Zhao, Mengzhao Wang, Yanqiu Zhao, Kejing Tang, Zhi‐Hua Li, Zhengbo Song, Yongsheng Li, Wu Zhuang, Bo Jin, Ying Cheng, Yanping Hu, Yanhong Gu, Lin Wu, Rui Ma, Qitao Yu, Yan Yu, Jun Zhao, Hui Zhao, Dongqing Lv, Yanhong Shang, Puyuan Xing, Jin Zhou, Xingya Li, Zhe Liu, Zhaoxia Dai, Guohao Xia, Xueqin Chen, Yi Ba, Chunmei Bai, Qingshan Li, Guangyu An, Weiguo Hu, Yinxiang Wang, Andrea Wang‐Gillam, Yuli Ding, Qiao Li, Zhiyue Rao
Topics & Concepts
MedicineClinical endpointKRASInternal medicineAdverse effectIncidence (geometry)Phases of clinical researchCancerGastroenterologyOncologyConfidence intervalClinical trialLung cancerColorectal cancerPhysicsOpticsLung Cancer Treatments and MutationsPI3K/AKT/mTOR signaling in cancerCancer therapeutics and mechanisms